[1]张小改 陈国芳 徐书杭 刘超.IgG4相关性甲状腺疾病新进展[J].国际内分泌代谢杂志,2020,40(03):163-168.[doi:10.3760/cma.j.issn.1673-4157.2020.03.005]
　Zhang Xiaogai,Chen Guofang,Xu Shuhang,et al.Update of IgG4-related thyroid diseases[J].International Journal of Endocrinology and Metabolism,2020,40(03):163-168.[doi:10.3760/cma.j.issn.1673-4157.2020.03.005]
点击复制

IgG4相关性甲状腺疾病新进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年03期
页码:
163-168
栏目:
综述
出版日期:
2020-05-20

文章信息/Info

Title:
Update of IgG4-related thyroid diseases
作者:
张小改 陈国芳 徐书杭 刘超
南京中医药大学附属中西医结合医院,江苏省中医药研究院内分泌科; 国家中医药管理局瘿病证治重点研究室 210028
Author(s):
Zhang Xiaogai;  Chen Guofang;  Xu Shuhang;  Liu Chao
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine; Jiangsu Province Academy of Traditional Chinese Medicine; Key Laboratory of TCM Syndrome & Treatment of Yingbing of State Administration of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
IgG4;  IgG4相关性甲状腺疾病;  里德尔甲状腺炎
Keywords:
IgG4;  IgG4-related thyroid disease;  Riedel's thyroiditis
DOI:
10.3760/cma.j.issn.1673-4157.2020.03.005
摘要:
IgG4相关性甲状腺疾病(IgG4-RTD)包括Riedel甲状腺炎(RT)、桥本甲状腺炎纤维样变型、IgG4相关性桥本甲状腺炎(IgG4-RHT)及伴高IgG4血症的Graves病。此外,IgG4可能与甲状腺癌发病有关。IgG4-RTD的发病机制尚不清楚,其诊断主要依据血IgG4水平和组织病理学检查。糖皮质激素是RT一线治疗方案,对于糖皮质激素不能诱导缓解及存在治疗禁忌证者,可单独或联合免疫抑制剂及生物抑制剂治疗。IgG4-RHT和伴高IgG4血症Graves病的治疗,仍以甲状腺激素替代和抗甲状腺药物治疗为主。
Abstract:
IgG4-related thyroid disease(IgG4-RTD)includes Riedel's thyroiditis(RT), fibrosing variant of Hashimoto's thyroiditis, IgG4 related Hashimoto's thyroiditis(IgG4-RHT), and Graves' disease with elevated serum IgG4. In addition, IgG4 may involve in the onset of thyroid cancer. The pathogenesis of IgG4-RTD is unclear, and its diagnosis is mainly based on the levels of serum IgG4 and histopathology. Glucocorticoid is the first-line treatment for RT, and for patients who cannot receive remission or have contraindications to glucocorticoids, immunosuppressants and biological inhibitors can be administrated alone or in combination with glucocorticoids. However, the therapy of IgG4-RHT and Graves' disease with elevated serum IgG4 still depend on thyroid hormone replacement and antithyroid therapy.

参考文献/References:

[1] Kamisawa T,Zen Y,Pillai S,et al.IgG4-related disease[J].Lancet,2015,385(9976):1460-1471.DOI:10.1016/S0140-6736(14)60720-0.
[2] Hamano H,Kawa S,Horiuchi A,et al.High serum IgG4 concentrations in patients with sclerosing pancreatitis[J].N Engl J Med,2001,344(10):732-738. DOI:10.1056/NEJM200103083441005.
[3] Kamisawa T,Funata N,Hayashi Y,et al.A new clinicopathological entity of IgG4-related autoimmune disease[J].J Gastroenterol,2003,38(10):982-984.DOI:10.1007/s00535-003-1175-y.
[4] Sato Y,Notohara K,Kojima M,et al.IgG4-related disease: historical overview and pathology of hematological disorders[J].Pathol Int,2010,60(4):247-258.DOI: 10.1111/j.1440-1827.2010.02524.x.
[5] Komatsu K,Hamano H,Ochi Y,et al.High prevalence of hypothyroidism in patients with autoimmune pancreatitis[J].Dig Dis Sci,2005,50(6):1052-1057.DOI:10.1007/s10620-005-2703-9.
[6] Kottahachchi D,Topliss DJ.Immunoglobulin G4-related thyroid diseases[J].Eur Thyroid J,2016,5(4):231-239.DOI:10.1159/000452623.
[7] Riedel BM. Die chronische, zur Bildung eisenharter Tumoren führende Entzündung der Schilddrüse[J]. Verh Dtsch Ges Chir, 1896, 25:101-105.
[8] Hay ID. Thyroiditis: a clinical update[J].Mayo Clin Proc,1985,60(12):836-843. DOI:10.1016/s0025-6196(12)64789-2.
[9] Falhammar H,Juhlin CC,Barner C,et al.Riedel's thyroiditis: clinical presentation, treatment and outcomes[J].Endocrine,2018,60(1):185-192.DOI:10.1007/s12020-018-1526-3.
[10] Simo～es CA,Tavares MR,Andrade NMM,et al. Does the intensity of IGG4 immunostaining have a correlation with the clinical presentation of Riedel's thyroiditis?[J].Case Rep Endocrinol,2018,2018:4101323.DOI:10.1155/2018/4101323.
[11] Stan MN,Sonawane V,Sebo TJ,et al.Riedel's thyroiditis association with IgG4-related disease[J].Clin Endocrinol(Oxf),2017,86(3):425-430.DOI:10.1111/cen.13238.
[12] Stan MN,Haglind EG,Drake MT.Early hypoparathyroidism reversibility with treatment of Riedel's thyroiditis[J].Thyroid,2015,25(9):1055-1059.DOI:10.1089/thy.2015.0212.
[13] Dahlgren M,Khosroshahi A,Nielsen GP,et al.Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum[J].Arthritis Care Res(Hoboken),2010,62(9):1312-1318.DOI:10.1002/acr.20215.
[14] Takeshima K,Inaba H,Ariyasu H,et al.Clinicopathological features of Riedel's thyroiditis associated with IgG4-related disease in Japan[J].Endocr J,2015,62(8):725-731.DOI:10.1507/endocrj.EJ15-0175.
[15] Li Y,Bai Y,Liu Z,et al.Immunohistochemistry of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis[J].Pathol Int,2009,59(9):636-641.DOI:10.1111/j.1440-1827.2009.02419.x.
[16] Jokisch F,Kleinlein I,Haller B,et al.A small subgroup of Hashimoto's thyroiditis is associated with IgG4-related disease[J].Virchows Arch,2016,468(3):321-327.DOI:10.1007/s00428-015-1893-6.
[17] 余洋,卢桂芝,高莹,等.IgG4阳性桥本甲状腺炎[J].中华内科杂志,2017, 56(5):381-384.DOI:10.3760/cma.j.issn.0578-1426.2017.05.016.
[18] Li Y,Zhou G,Ozaki T,et al.Distinct histopathological features of Hashimoto's thyroiditis with respect to IgG4-related disease[J].Mod Pathol,2012,25(8):1086-1097.DOI:10.1038/modpathol.2012.68.
[19] Zhang J,Zhao L,Gao Y,et al.A classification of Hashimoto's thyroiditis based on immunohistochemistry for IgG4 and IgG[J].Thyroid,2014,24(2):364-370.DOI:10.1089/thy.2013.0211.
[20] Katz SM,Vickery AL Jr.The fibrous variant of Hashimoto's thyroiditis[J].Hum Pathol,1974,5(2):161-170.DOI:10.1016/s0046-8177(74)80063-8.
[21] Deshpande V,Huck A,Ooi E,et al.Fibrosing variant of Hashimoto thyroiditis is an IgG4 related disease[J].J Clin Pathol,2012,65(8):725-728.DOI:10.1136/jclinpath-2011-200485.
[22] Takeshima K,Inaba H,Furukawa Y,et al.Elevated serum immunoglobulin G4 levels in patients with Graves' disease and their clinical implications[J].Thyroid,2014,24(4):736-743.DOI:10.1089/thy.2013.0448.
[23] 江帆,陈国芳,徐书杭,等.高IgG4水平Graves病临床特征研究[J].中国实用内科杂志,2018,38(1):52-55.DOI:10.19538/j.nk2018010114.
[24] Torimoto K,Okada Y,Kurozumi A,et al.Clinical features of patients with Basedow's disease and high serum IgG4 levels[J].Intern Med,2017,56(9):1009-1013.DOI:10.2169/internalmedicine.56.7824.
[25] Martin CS,Sirbu AE,Betivoiu MA,et al.Serum immunoglobulin G4 levels and Graves' disease phenotype[J].Endocrine,2017,55(2):478-484.DOI:10.1007/s12020-016-1157-5.
[26] Hiratsuka I,Yamada H,Itoh M,et al.Changes in serum immunoglobulin G4 levels in patients with newly diagnosed Graves' disease[J].Exp Clin Endocrinol Diabetes,2020,128(2):119-124.DOI:10.1055/a-0669-9333.
[27] Yu SH,Kang JG,Kim CS,et al.Clinical implications of immunoglobulin G4 to Graves' ophthalmopathy[J].Thyroid,2017,27(9):1185-1193.DOI:10.1089/thy.2017.0126.
[28] 何志伟,陈国芳,刘超.IgG4相关性眼病的诊治进展[J].中国实用内科杂志,2018, 38(10):30-33.DOI:10.19538/j.nk2018100107.
[29] Nishihara E,Hirokawa M,Ito M,et al.Graves' disease patients with persistent hyperthyroidism and diffuse lymphoplasmacytic infiltration in the thyroid show no histopathological compatibility with IgG4-related disease[J].PLoS One,2015,10(7):e0134143.DOI:10.1371/journal.pone.0134143.
[30] Tali F,Ozkök G,Argon A,et al.The role of IgG4(+)plasma cells in the association of Hashimoto's thyroiditis with papillary carcinoma[J].APMIS,2014,122(12):1259-1265.DOI:10.1111/apm.12297.
[31] Yu Y,Zhang J,Lu G,et al.Clinical relationship between IgG4-positive Hashimoto's thyroiditis and papillary thyroid carcinoma[J].J Clin Endocrinol Metab,2016,101(4):1516-1524.DOI:10.1210/jc.2015-3783.
[32] Umehara H,Okazaki K,Masaki Y,et al.Comprehensive diagnostic criteria for IgG4-related disease(IgG4-RD),2011[J].Mod Rheumatol,2012,22(1):21-30.DOI:10.1007/s10165-011-0571-z.
[33] 陈国芳,江帆,刘超.IgG4相关性疾病:从认知到展望[J].中国实用内科杂志,2018, 38(10):22-25.DOI:CNKI:SUN:SYNK.0.2018-10-00.
[34] Yu Y,Yu N,Lu G,et al. Hashimoto's thyroiditis with elevated serum IgG4 concentrations is not equivalent to IgG4 Hashimoto's thyroiditis[J].Clin Endocrinol(Oxf),2018,88(6):943-949. DOI:10.1111/cen.13596.
[35] Lin W,Zhang P,Chen H,et al.Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease[J].Arthritis Res Ther,2017,19(1):25.DOI:10.1186/s13075-017-1231-2.
[36] Tang J, Cai S, Ye C,et al. Biomarkers in IgG4-related disease: a systematic review[J].Semin Arthritis Rheum,2019,pii:S0049-0172(19)30329-4.DOI:10.1016/j.semarthrit.2019.06.018.
[37] Kottahachchi D,Topliss DJ.Immunoglobulin G4-related thyroid diseases[J].Eur Thyroid J,2016,5(4):231-239.DOI:10.1159/000452623.
[38] Kamisawa T,Okazaki K,Kawa S,et al.Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis[J].J Gastroenterol,2014,49(6):961-970.DOI:10.1007/s00535-014-0945-z.
[39] Fatourechi MM,Hay ID,McIver B,et al.Invasive fibrous thyroiditis(Riedel thyroiditis):the Mayo Clinic experience, 1976-2008[J].Thyroid,2011,21(7):765-772.DOI:10.1089/thy.2010.0453.
[40] Takahashi Y,Takahashi E,Hiromatsu Y,et al.Immunoglobulin G4-positive staining of orbital lesions in thyroid eye disease: report of two cases[J].Mod Rheumatol,2018,28(5):893-896.DOI:10.3109/14397595.2016.1174421.
[41] Khosroshahi A,Wallace ZS,Crowe JL,et al.International consensus guidance statement on the management and treatment of IgG4-related disease[J].Arthritis Rheumatol,2015,67(7):1688-1699.DOI:10.1002/art.39132.
[42] Carruthers MN,Topazian MD,Khosroshahi A,et al.Rituximab for IgG4-related disease:a prospective, open-label trial[J].Ann Rheum Dis,2015,74(6):1171-1177.DOI:10.1136/annrheumdis-2014-206605.
[43] Soh SB,Pham A,O'Hehir RE,et al.Novel use of rituximab in a case of Riedel's thyroiditis refractory to glucocorticoids and tamoxifen[J].J Clin Endocrinol Metab,2013,98(9):3543-3549.DOI:10.1210/jc.2012-4050.

相似文献/References:

[1]李秀娟,刘红梅.IgG4相关桥本甲状腺炎的研究进展[J].国际内分泌代谢杂志,2014,(04):257.[doi:10.3760/cma.j.issn.1673-4157.2014.04.012]
　Li Xiujuan,Liu Hongmei..Recent progress of IgG4-related Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(03):257.[doi:10.3760/cma.j.issn.1673-4157.2014.04.012]

备注/Memo

备注/Memo:
通信作者:陈国芳,Email:chenguofang9801@126.com; 刘超,Email:liuchao@nfmcn.com
基金项目:国家自然科学基金(81800756); 江苏省六大人才高峰(WSN-035)
Corresponding author: Chen Guofang, Email: chenguofang9801@126.com; Liu Chao, Email: liuchao@nfmcn.com
Fund program:National Natural Science Foundation of China(81800756); Six Talent Peaks Project in Jiangsu Province(WSN-035)
更新日期/Last Update: 2020-05-20